The patient home collection that has emerged as a necessity out of the pandemic has provided a glimpse as to what “access” means in the home or alternative centers of care. In this, we have demonstrated a big part of the future of medicine.
In the classic home collection environment, a bad sample means bad data. The processes and technologies that have allowed us to test in the millions at home have become a key focus of success and will likely lead to other avenues of personalized medicine.
Tim Stenzel shares his thoughts on the amazing technologies intended for healthcare setting like labs & clinics and pivots these into the home, getting similar performance as compared to Point of Care settings.
The convergence of empowered personal medicine, access, rapid rate of innovation are some of the silver linings that have emerged out of the COVID pandemic. There were technologies in the pipeline that, in turn, allowed us to accelerate these technologies and practices by a hyper-focus that was required to respond to the pandemic.
Danelle Miller, the Vice President of Global Regulatory Policy and Intelligence with Roche Diagnostics and Timothy Stenzel who is a Director, In Vitro Diagnostics and Radiological Health with the FDA discuss the massive investment made by the US Government. This has been a tremendous success and supported ramped up production, new technologies introduced into the home, and how and where testing is performed.